Role of high-dose chemotherapy and autologous stem cell support in treatment of breast cancer

S. E. Myers, S. F. Williams*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Patients with metastatic breast cancer with chemotherapy-sensitive disease, good performance status, and few sites of metastatic disease are the best candidates for high-dose chemotherapy and autologous stem cell reinfusion. Even in this selected subset of patients with metastatic breast cancer, at best 30% to 40% will maintain a complete remission beyond 2 years. In the high-risk adjuvant setting, high-dose chemotherapy appears efficacious; however, results from ongoing randomized prospective trials will not be available for several years.

Original languageEnglish (US)
Pages (from-to)631-645
Number of pages15
JournalHematology/Oncology Clinics of North America
Volume7
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Role of high-dose chemotherapy and autologous stem cell support in treatment of breast cancer'. Together they form a unique fingerprint.

Cite this